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Summary 
Genetic modification  of many types of mouse tumors to express the B7-1  or B7-2 molecules, 
natural  ligands  for the  T  cell-costimulatory  molecule  CD28,  increases  their immunogenicity. 
However,  even after transfection  with the B7-1  and/or B7-2  genes, poorly immunogenic  tu- 
mors  fail  to  elicit  an  efficient  immune  response.  We  report  here  that  two  such  tumors,  the 
Agl04A  sarcoma  and  the  K1735-M2  melanoma,  become  immunogenic  after  transfection  of 
the  genes  encoding  murine  B7-1  together with  CD48,  which  is the  natural  ligand  for CD2. 
Tumor-specific CD8 + cytotoxic T  lymphocytes were readily generated and were effective for 
adoptive  immunotherapy  of metastasis induced  by wild-type Agl04A  sarcoma cells.  A  similar 
approach may be useful for developing therapy for other poorly immunogenic  tumors, includ- 
ing those in humans. 
T 
CR  confers specific recognition  of peptide antigens in 
the  context  of MHC  molecules  (1).  Efficient  activa- 
tion of T  cells, however,  requires costimulatory signals  (2). 
Several  T  cell  surface proteins  and  their  respective  ligands 
on APC are involved in both increasing the strength of ad- 
hesion  between  the  interacting  cells and  costimulating  the 
T  cells to respond appropriately (2, 3). Among these mole- 
cules,  the  CD28  and  CD2  proteins  on  T  cells  play  such 
dual roles in T  cell function. 
Interaction  between  CD2  and  its  natural  ligand  CD48 
(4), the structural  and functional  homologue  of the human 
LFA-3 molecule, is required for the generation of a T  cell- 
mediated  immune  response.  Prevention  of this  interaction 
by injecting mice with either anti-CD2  or anti-CD48  anti- 
bodies  induces  sustained  unresponsiveness  of both  CD4 + 
and  CD8 +  T  cells  to  antigen  stimulation  (5).  Administra- 
tion  of a  combination  of anti-CD2  and  anti-CD48  anti- 
bodies  can  induce  long term acceptance  of allogenic  heart 
grafts (6).  Although  the role of the CD2  signaling pathway 
in  the  induction  of antitumor  immunity  remains  largely 
unknown,  costimulation  through  the  B7-CD28  pathway 
plays an important role in eliciting antitumor immunity (7). 
Many B7-negative  tumors  can  be  manipulated  to  become 
more immunogenic by transfer of genes encoding the B7-1 
or  B7-2  molecules,  whereas  several  poorly  immunogenic 
tumors  have failed  to  induce  immune  response  even  after 
transfer of B7-1  (8)  and/or B7-2  (9). 
We  speculated  that  lack  of  immunogenicity  can  be 
caused  by  a  deficiency  to  present  tumor  antigens  at  the 
level  required  for  triggering  a  TCIL  signal.  If that  is  the 
case,  strengthening  the  adhesion  and  signaling  between 
TC1L  and  MHC-presented  antigens  on  poorly  immuno- 
genic  tumors  may improve the  generation  of antitumor  T 
cell  response.  This  possibility  was  tested  with  two  such 
tumors,  mouse  sarcoma  Agl04A  (10)  and  melanoma 
K1735-M2  (11). 
Materials  and Methods 
Mice and Cell Lines.  Female  C3H/HeN  (C3H)  mice,  4--6 
wk old, were purchased from The Jackson Laboratory (Bar Har- 
bor, ME).  Agl04A,  a spontaneous fibrosarcoma of C3H  (H-2  k) 
orion,  and  Agl04B,  a  second  spontaneous  tumor in  the  same 
mouse  (10),  were  gifts  from Dr.  Hans  Schreiber  (University  of 
Chicago,  Chicago,  IL).  The  B7-1  transfectant  of Agl04A  cells 
(renamed  here  B7+Agl04A)  was  described  (8).  The  C3H- 
derived  K1735-M2  melanoma,  its  B7-1  transfectant  (reference 
12; renamed here B7+K1735-M2),  and p97-transfectant 2A (11), 
have  been  described  previously,  as  were  the  UV4102Pro  and 
UV6132APro  fibrosarcoma  lines  (10).  The  control  Agl04A 
(Mock.Agl04A) and K1735-M2  (Mock.K1735-M2) lines,  which 
were  transduced  with  retrovirus  without  insert,  have  been  de- 
scribed  (8).  The  EL4  thymoma  is  of C57B1/6  (H-2  b)  origin. 
YAC-I is an NK-sensitive lymphoma. The latter two lines  were 
purchased  from  American  Type  Culture  Collection  (ATCC, 
Rockville,  MD).  ConA-stimulated  lymphoblasts were  prepared 
as described (12). 
Cloning and Transfection of Murine CD48.  A  DNA  fragment 
encoding  the  entire  open  reading  frame of murine  CD48  (13) 
was  amplified  by  reverse  transcription-coupled  PCR  of total 
1LNA prepared from EL4 cells. The sense primer (5'-GCTAAA- 
GCTTCTCGAACCGCCACCATGTGCTTCATAAAACAGG- 
GAT3') consisted of an oligonucleotide corresponding to nude- 
otides  51-72  of murine  CD48  cDNA  plus  restriction  sites  for 
HindlII and XhoI.  The  antisense  primer (5'-CGTAAAGCTT- 
CTCGGAGTCTAGAGTTCCTTGTCAGGTTAACAG-3') cor- 
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sites for HindlIl, XhoI, and XbaI. The PCR product was directly 
cloned into the vector pR.C/CMV (Invitrogen, San Diego, CA). 
The  structure  of the  resulting  construct  pRc/CMV-mCD48  is 
shown in Fig. 1 A. The cell lines were transfected with this vec- 
tor by electroporation, and the transfectants  were selected as de- 
scribed previously (11). 
Antibodies, Immunostaining, and Flow Cytometry Analysis.  Pu- 
rified and FITC- or PE-conjugated mAbs to MHC-K  k, D k, I-A  k, 
I-E  k, B7-1  (CD80), B7-2 (CD86), the intracellular adhesion mol- 
ecule  (ICAM)-I  and  ICAM-2,  the vascular cell adhesion mole- 
cule  (VCAM)-I,  the  heat  stable  antigen  (HSA),  CD48,  CD40, 
and the CD40 ligand (CD40L) were purchased from PharMingen 
(San  Diego,  CA).  The  mAbs  116-13.1  (anti-CD8)  and  GK1.5 
(anti-CD4) were purified from culture supernatant  of the respec- 
tive  hybridomas  (ATCC),  and  mAb  10.2  (anti-human  CD5) 
(ATCC) was used as a control. Rabbit polyclonal antibody, anti- 
Asialo  GM1,  was  purchased  from  Wako  Bioproducts  (Rich- 
mond,  VA).  For  immunofluorescence  staining,  single  cell  sus- 
pensions  from either Agl04A or K1735-M2  were incubated  on 
ice  for  30  rain  with  FITC-conjugated  mAb  or  PE-conjugated 
mAb.  After being washed  twice with  medium,  they were ana- 
lyzed by FACS  | 
Immunization Studies.  Mice, in groups  of 5  or  10,  were in- 
jected intraperitoneally with 5 ￿  106 and subcutaneously with 5 ￿ 
106  y-irradiated  (2,500  rad)  tumor  cells.  14  d  later,  they  were 
challenged subcutaneously  with  the  respective wild-type  tumor 
cells at  106/mouse for wt Agl04A and at 2  ￿  106/mouse for wt 
K1735-M2,  and  tumor size was  measured  at regular intervals as 
described previously (11). 
Generation and Assay of CTL Activity.  C3H  mice  were  im- 
munized with irradiated  (2,500  rad)  Agl04A transfectants  as de- 
scribed above. 2-3 wk later, single-cell suspensions were prepared 
from the spleen and cocultivated for 5 d with ~/-irradiated (10,000 
rad)  wt  Agl04A  cells  in  a  24-well plate  (Costar  Corp.,  Cam- 
bridge, MA).  For the generation of T  cell lines, spleen cell cul- 
tures  were  restimulated  every  7-10  d  with  ",/-irradiated  wt  or 
CD48+Ag104A  cells  in  the  presence  of irradiated  (3,000  rad) 
splenocytes from C3H mice and human recombinant IL-2 (Cetus 
Corp., Emeryville, CA) at 5 U/m] (11).  CTL clones were gener- 
ated  by limiting dilution.  Cytolytic  activity was  examined  in  a 
standard 4-h 51Cr release assay at different E/T ratios as indicated 
in  the  figures.  In  T  cell subset  depletion  experiments,  effector 
cells at "al06/ml were incubated for 30 min on ice with 30  ~tg/ 
ml of the indicated mAb and were subsequently treated with 1:100 
diluted rabbit complement (Cedarlane Laboratories, Homby, Can- 
ada)  and washed three times before use. 
Adoptive lmmunotherapy of Micmmetastasis Induced by wt Ag l O4A 
Sarcoma.  C3H mice, in groups of 5 or 10,  were injected intra- 
venously with AgI04A tumor cells at  106/mouse.  3  d  later they 
were  injected  intravenously  with  5  ￿  106  cells from  the  YL1 
CTL line (see  text) or from a C3H-derived anti-H-2  a CTL line, 
which was used as a control, and they were given daily intraperi- 
toneal injections of 104 U  of human recombinant IL-2 in PBS for 
3  d.  Other groups of mice were treated with the same dosage of 
IL-2 or PBS.  3  wk after tumor injection,  the mice were killed, 
the lungs were removed and fixed in Bouin's solution, and meta- 
static  nodules were  counted  under a  dissecting microscope; 200 
metastatic  nodules  was  the  upper  limit that  could be  accurately 
counted.  In some experiments,  the  mice  were  monitored  daily 
for survival. When  a moribund  mouse was found,  it was killed, 
and a gross pathology examination was performed to identify me- 
tastases. 
Results 
FACS  |  analysis  with  specific  mAbs  revealed  that  the 
Agl04A  line  expresses  a  high  level  of  H-2K ~,  D k,  and 
VCAM-1,  whereas it does not express MHC  class II or sev- 
eral potential costimulatory molecules, such as B7-1, B7-2, 
CD48,  ICAM-1,  ICAM-2,  HSA, CD40, and CD40L.  The 
K1735-M2  line  expresses  very low levels of MHC  class  I 
and  II  molecules and  has  none  of the accessory  molecules 
tested for (data not shown).  A  recombinant plasmid, pRC/ 
CMV.mCD48,  containing  the  murine  CD48  cDNA,  was 
constructed  (Fig.  1).  Four  tumor  lines,  wt  Agl04A, 
B7+Agl04A  (12),  wt K1735-M2,  and  B7+K1735-M2  (8, 
11),  were transfected with  this vector, and clones obtained 
from  each  line  were  screened  by  FACS  |  analysis  for  the 
expression of CD48.  Three to five clones from each tumor 
line with  stable  cell surface  expression  of CD48,  B7-1,  or 
both  were  picked.  After in  vivo tumorigenicity  tests  (Fig. 
2),  one clone from each line was selected for further exper- 
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Expression of CD48 and B7-1 molecules on tumor cells. (A) 
Structure  of the pRC/CMV.mCD48 contruct.  The murine CD48 open 
reading frame is driven by the CMV promoter.  The vector contains the 
neomycin resistant gene (neo) for drug selection,  (/3) Cell surface expres- 
sion  of murine CD48  and B7-1  on transfected  Agl04A lines. The wt 
Agl04A,  CD48+Ag104A,  and  B7+CD48+Ag104A  cells were  stained 
with FITC-conjugated anti-CD48 mAb, anti-B7-1  mAb, or the control 
mAb and subjected to FACS  |  analysis as described in Materials and Meth- 
ods. A total of 5,000 cells were analyzed for each sample. (C) Cell surface 
expression  of murine CD48 and  B7-1  on  transfected  K1735-M2  cells. 
The wt K1735-M2,  CD48+K1735-M2,  and B7+CD48+K1735-M2  cells 
were stained and analyzed as described in B. 
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Figure  2.  Tumorigenicity and immunogenicity of the transfectants  de- 
rived from the Ag104A and K1735-M2 cells in C3H mice. C3H mice, in 
groups of 10, were injected subcutaneously with the transfectants from 
Ag104A at 106/mouse (/t) or from K1735-M2 at 2 X  106/mouse (C). 
Tumor size was assessed  at regular intervals. The experiments were termi- 
nated when some tumors reached 20-25 mm in diameter, severe ulcer- 
ation or bleeding had developed, or the mice had died. For immuniza- 
tion, C3H mice, in groups of 5 or 10, were injected subcutaneously and 
intraperitoneaUy with  PBS  or with  irradiated (2,500 rad) transfectants 
from Agl04A cells (B) or from K1735-M2 cells (D) at 5 X 106. 2-3 wk 
later,  they were  challenged subcutaneously at  a  distant site with  wt 
Agl04A cells (B) or with wt K1735-M2 cells (D). The results are ex- 
pressed as mean diameters (in millimeters) of tumors from all mice in the 
group. Error bars represent SD of the means. Similar results were ob- 
tained in a repeat experiment with each cell line. 
iments.  The  CD48  and B7-1  expression in several repre- 
sentative clones from both Agl04A and K1735-M2  cells is 
shown in Fig. 1, 
The  tumorigenicity  of the  transfectants  was  tested  by 
subcutaneous injection of C3H  mice with cells from each 
clone at a minimal tumorigenic dose (8). The wt Agl04A 
tumor  grew  progressively  in  all  mice,  as  did  tumors 
induced  by  CD48+Ag104A  and  B7+Agl04A  cells.  In 
contrast,  transfectants  expressing  both  CD48  and  B7-1 
(B7+CD48+Ag104A)  grew more slowly or not at all in the 
mice  (Fig.  2  A).  6  out  of  10  mice  inoculated  with 
B7+CD48+Ag104A remained tumor-free for >2 mo. Sim- 
ilar  results  were  obtained  using  K1735-M2  transfectants 
(Fig. 2  C). 
C3H mice, in groups of 5 or 10, were immunized by the 
double  transfectants  from  either  Ag104A  or  K1735-M2 
and  then  challenged  with  wt  tumor  cells  to  examine 
whether they had developed any protective tumor immu- 
nity.  All mice  immunized  with  B7+CD48+Ag104A  cells 
were resistant to the wt tumor challenge, whereas mice im- 
munized  with  CD48+Ag104A  or  given PBS  as  a  control 
displayed no protective immunity (Fig. 2/3). However, the 
protective immunity  induced by B7+CD48+Ag104A  was 
not long lasting, since 60% of the mice developed progres- 
sive tumors at the injection site that were detected 55 d  af- 
ter tumor challenge. Similar results were obtained after im- 
munization  of  mice  with  B7+CD48+K1735-M2  cells: 
although  all  mice  immunized  with  mock-,  CD48-,  or 
B7-1-transfected  K1735-M2  cells displayed no  protective 
immunity,  fewer  tumors  grew  out  in  mice  immunized 
with  B7+CD48+K1735-M2  cells  (Fig.  2  D).  40%  of the 
mice were resistant to outgrowth of cells from wt K1735- 
M2  tumor during the initial 4  wk,  although  only 20%  of 
them were tumor free 5  wk after challenge. We conclude 
that growth of Agl04A and K1735-M2  was inhibited and 
that  protective immunity  could be  induced  against them, 
but only when both CD48 and B7-1 were expressed in the 
immunizing tumor cells. 
Splenocytes  from  mice  immunized  with  the  double 
transfectants were harvested and further stimulated in vitro by 
cocultivation with irradiated wt Agl04A cells for 5 d. Sub- 
sequently, they were tested for CTL  activity in a standard 
SlCr release assay. As indicated in Fig. 3, bulk-cultured spleen 
cells from  mice  immunized with  B7+CD48+Ag104A  re- 
vealed a high level of CTL activity against wt Agl04A cells 
(Fig.  3  A).  In  contrast,  bulk-cultured  spleen  cells from 
the  mice  immunized  with  CD48+Ag104A  (Fig.  3  B)  or 
B7+Agl04A (12) did not show any significant CTL activity 
to wt Agl04A targets. The bulk-cultured CTL from mice 
immunized  with  B7+CD48+Ag104A  also  lysed the  NK- 
sensitive YAC-1  cell line, albeit at a lower level. 
In  an  attempt  to  obtain  tumor-reactive  CTL  lines for 
adoptive immunotherapy,  bulk-cultured spleen cells were 
repeatedly stimulated in vitro with irradiated Agl04A cells, 
and they were then tested for CTL  activity. A  representa- 
tive CTL hne, YL1  (Fig. 3  C), and a clone, c18 (Fig. 3 D), 
had high cytolytic activity against wt Agl04A cells, whereas 
there was no lysis of a panel of other targets, including the 
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Agl04A.  C3H mice were  injected intravenously with  wt 
Agl04A cells at  106/mouse,  and 4  d  later the  mice were 
treated with either YL1  CTL plus IL-2 or IL-2 alone.  In 
contrast to the formation of lung metastases in mice treated 
with IL-2 alone, six out of seven mice treated by YL1  plus 
IL-2 were free of lung tumors at day 20. The antimetastatic 
effect of the CTL was specific for Agl04A tumor since the 
same  treatment did not inhibit the  growth  of lung meta- 
static  tumors  induced  by  either  Agl04B  or  K1735-M2 
(Table l). The effect of anti-Agl04 CTL on survival of tu- 
mor-beating mice was also observed. Intravenous injection 
of mice with wt Agl04A cells at 106/mouse killed 100% of 
the mice within 50  d.  In contrast,  10  out of 10  mice in- 
jected  with  cells  from  the  YL1  line plus  IL-2  remained 
alive after  >160  d,  whereas  the  mice  treated  with  either 
IL-2 or  IL-2 combined with a  control CTL line did not 
live any longer than the PBS-treated group (Fig. 4).  Mice 
that died were shown to have tumor growth in the lungs, 
and in some cases also in the back, neck, and bones. 
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syngeneic tumor lines Agl04B, UV4102Pro, UV6132APro, 
2A,  syngeneic  ConA lymphoblasts,  and  several  allogenic 
tumor lines, including EL4 (H-2  b) (Fig. 3,  C  and D), P815 
(H-2b), and L1210 (H-2  b)  (Fig. 3 E).  However, both YL1 
and c18 lysed YAC-1  at a  significant level. The YL1  line 
has been passaged in vitro over a  10-mo period and retains 
its cytolytic activity against wt Agl04A. Incubation of the 
YL1  line with an anti-CD8 mAb,  but not with an anti- 
CD4 mAb or with an anti-Asialo GM1  antiserum, in the 
presence of complement, eliminated the  cytolytic activity 
(Fig.  3  it:), whereas  the  same  treatment  with  anti-Asialo 
GM 1 antiserum abrogated NK activity of spleen cells from 
mice injected with polyI:C (14)  (data not shown). We con- 
clude  that  CD8 +,  MHC  class  I-restricted  CTL  that  are 
specfic  for  Agl04A  can  be  generated  from  mice  immu- 
nized with B7+CD48+Ag104A cells and that they can be 
maintained in vitro for >  10 mo. 
We then test whether anti-Agl04 CTL can be used for 
the  treatment  of pulmonary micrometastasis  induced  by 
E/T  Err 
----4a---  Agl04A 
----0---  Agl04B 
--O--  P815 
L1210 
YAC-1 
None 
+  C' 
----O---  Anti-CD4 + C' 
Anti-CD8 + C' 
Anti-Asialo GM 1 + C' 
Figure 3.  Cytolytic  activity  of CTL generated from mice immunized  with BT+CI)48*Ag104A. C3H mice were injected subcutaneously  with either 
CD48*B7+Ag104A cells (A) or CD48+Ag104A cells (/3) at 10~'/mouse. 10 d later, tumor nodules were removed surgically. Spleen ceils were prepared 
14 d after injection and were cocultivated  with y-irradiated  wt Ag104A cells  for 5 d. CTL activity  against 5~Cr_labeled  target cells, as indicated,  was mea- 
sured as described in Materials and Methods. Cytolytic  activity  ofYL1 (C and E) and c18 clone (D) of CTL against 5lCr-labeled  target cells, as indicated, 
was also measured. For T cell subset depletion experiments (E), cells from the YL1 line were pretreated with anti-CD4 and anti-CD8 mAbs or anti- 
Asialo GMI antiserum  in the presence of complement, as described in Materials and Methods before assay for their cytolytic  activity. 
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We have demonstrated that coexpression of CD48 with 
B7-1  in  two  classically  poorly immunogenic  tumors,  the 
Agl04A sarcoma and the K1735-M2 melanoma, made them 
immunogenic, as indicated by their inhibited growth in syn- 
geneic  C3H  mice and by their  ability to induce a  certain 
level of protective immunity against challenge with wt tumor 
cells.  Furthermore, tumor-specific CTL could be generated 
in vitro  (Fig.  3)  and used for adoptive immunotherapy  to 
cure micrometastasis  induced by wt Agl04  cells  (Fig.  4). 
Our results  suggest that poor immunogenicity of tumors 
does not always reflect an inherent  lack of tumor antigens 
or failure of processing/presentation of such antigens. 
Transfection of both CD48 and B7-1 was required for in- 
duction of immunity against Agl04A and K1735-M2 since 
tumor cells  expressing  either the  CD48  or the B7-1  gene 
alone  were  poorly  immunogenic  (Fig.  2).  There  is  evi- 
dence that CD2 signaling can stimulate the signal transduc- 
tion pathway in a  manner  similar  to  that  of TCR-MHC 
antigen ligation  (3).  Another consequence of CD48-CD2 
interaction  is  an  increased  cell-cell  adhesion  (3),  and  this 
may also engage a greater number of receptor-ligand pairs. 
CD48 transfection into tumor cells may, therefore, elevate 
the  signal  delivered  by MHC-presented  tumor antigen  to 
the threshold  critical for triggering the TCP...  The expres- 
sion of the E7 protein of human papilloma virus type 16, in 
conjunction  with  B7-1,  makes  K1735-M2  highly immu- 
nogenic (11), demonstrating that this tumor line has the ma- 
chinery needed for antigen processing/presentation,  despite 
an  undetectable  MHC  class  I  expression  according  to 
FACS  |  analysis  (Table  1).  However,  immunization  by 
B7+CD48+K1735-M2  appears  to  be  less  effective  in  in- 
ducing systemic immunity  (Fig.  2  D)  than  that seen with 
the  Agl04A double  transfectant  (Fig.  2  B).  This  may be 
caused by a lack  of other  accessory molecules  and/or  the 
Table  1.  Treatment  of Mice with Lung Micrometastasis by 
Adoptive Transfer of the Anti-AglO4A CTL Line YL1 
Tumor  YL1  No. lung metastases 
Agl04A  +  0, 0, 4, 0, 0, 0, 0, 0* 
-  11,8,12,7,6,5,1 
Agl04B  +  15, 16, 12, 18, 5, 10, 8 
-  2,  10, 24,  17, 11, 2,  5,  8 
KI735-M2  +  >200 (in all six mice) 
-  >200 (in all five mice) 
C3H mice were injected intravenously with  10  6 tumor cells as indi- 
cated. 4 d after tumor inoculation, mice were injected intravenously 
with 5 ￿  106 cells ofYL1 CTL, followed by intraperitoneal injection 
with 104 U of  recombinant human IL-2; injection of IL-2 was repeated 
once a day for 3 consecutive days. Control groups received IL-2 treat- 
ment without CTL. 20 d after tumor inoculation, mice were killed and 
the  number  of lung metastases from each individual mouse was re- 
corded. 
*Significantly different from the number  of metastases obtained with 
control group without injecfon ofYL1 CTL (P <0.01). 
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Figure  4.  Cure of 3-d pulmonary micrometastasis of wt AgI04A cells 
by adoptive transfer ofYL1 CTL. Mice, in groups of 10, were injected 
intravenously with wt Agl04A cells at 106/mouse. 3 d later they were 
treated with 5 ￿  106 cells ofYL1 CTL line by intravenously  injection and 
followed the next day with an intraperitoneal injection of 104 U of re- 
combinant human IL-2 once a day for 3 d. Control groups included mice 
injected with either PBS alone, IL-2 alone, or a combination of the con- 
trol CTL line and IL-2. The mice were monitored daily for survival. Sim- 
ilar results were obtained with each CTL line in a repeat experiment. 
very low expression of MHC class I molecules on K1735-M2 
cells,  whereas  Agl04A  cells  express  high  levels  of MHC 
class I and VCAM-1  molecules (Table  1).  It is noteworthy 
that  although  the  protective  immunity  was  induced  by 
CD48 and B7-1  double transfectants,  many immune mice 
eventually developed tumors (Fig. 2, B and D). The possi- 
bilities  that the tumors lose antigen or MHC  class I mole- 
cules so as to escape the immune destruction are under in- 
vestigation. 
CD2  is  expressed  by 80-90%  of human  NK  cells,  and 
expression of CD58 and CD59 (ligands for CD2)  in target 
cells can activate NK cells (15), as can B7-CD28 costimula- 
tion  (16).  This  may  explain  the  lysis  of YAC-1  cells  by 
bulk-cultured  spleen  cells  from  mice  immunized  with 
B7+CD48+Ag104A  (Fig.  3  A).  The  CTL  activity against 
Agl04A  cells  observed  in  our  studies  is,  however,  not 
likely to be mediated by NK cells, since the YL1  line and 
the  c18  clone  behave  as  typical  MHC  class  I-restricted 
CD8 +  CTL  selective  for  Agl04A  cells,  except  for  their 
ability to lyse YAC-1 cells (Fig. 3, C  and/9).  The fact that 
the lysis  on Agl04A cells was not eliminated  by treatment 
of the YL1 line with an anti-Asialo GM1 antiserum (Fig. 3 
E), combined with published evidence that antigen-specific 
CTL can be promiscuous by lysing a variety of tumor cells 
(17),  supports  this  possibility.  It  is  noteworthy  that  our 
CTL could be propagated in vitro by exposure to irradiated 
wt Agl04A cells,  that is, that it did not require the presence 
of B7 and CD48 in the Agl04A cells.  This emphasizes that 
the expression of CD48 and B7-1 in the tumor cells is pri- 
marily needed for the in vivo priming of the CTL. 
It remains to be explored whether the poor immunoge- 
nicity of other tumors can also be reversed by the transfec- 
tion of both CD48 and B7-1.  If so, an approach similar to 
that  described  here  may become  useful  for  the  develop- 
ment  of therapy  of human  malignancies,  which  are  nor- 
really poorly immunogenic. 
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